Targeting carbonic anhydrase IX by nitroimidazole based sulfamides enhances the therapeutic effect of tumor irradiation: A new concept of dual targeting drugs
Abstract:A newly designed nitroimidazole and sulfamide dual targeting drug reduces hypoxic extracellular acidification, slows down tumor growth at nontoxic doses and sensitizes tumors to irradiation all in a CAIX dependent manner, suggesting no "off-target" effects. Our data therefore indicate the potential utility of a dual drug approach as a new strategy for tumor-specific targeting.
“…CA IX also contributes to therapy resistance, because tumors expressing high CA IX levels are less responsive to experimental therapy, and inhibition of CA IX catalytic activity significantly improves their chemo-or radiosensitivity [79,80]. Similarly, CA IX inhibition can enhance the effect of anti-angiogenic therapy with anti-VEGF antibody [64].…”
Section: The Roles Of Ca IX In Cancermentioning
confidence: 99%
“…Last, but not least, a very interesting design was adopted in development of dual targeting bioreductive nitroimidazole-based anti-CA IX sulfamide drug (DH348), which was shown to reduce tumor growth in mice and sensitize tumors to irradiation in a CA IX-dependent manner [80]. This dual-activity compound appears more promising than the single activity CA inhibitors due to combination of hypoxia-related selectivity/activation typical for the bioreductive drugs and binding to CA IX, which is present on the surface of the hypoxic cells.…”
“…CA IX also contributes to therapy resistance, because tumors expressing high CA IX levels are less responsive to experimental therapy, and inhibition of CA IX catalytic activity significantly improves their chemo-or radiosensitivity [79,80]. Similarly, CA IX inhibition can enhance the effect of anti-angiogenic therapy with anti-VEGF antibody [64].…”
Section: The Roles Of Ca IX In Cancermentioning
confidence: 99%
“…Last, but not least, a very interesting design was adopted in development of dual targeting bioreductive nitroimidazole-based anti-CA IX sulfamide drug (DH348), which was shown to reduce tumor growth in mice and sensitize tumors to irradiation in a CA IX-dependent manner [80]. This dual-activity compound appears more promising than the single activity CA inhibitors due to combination of hypoxia-related selectivity/activation typical for the bioreductive drugs and binding to CA IX, which is present on the surface of the hypoxic cells.…”
“…All these compounds showed efficacy in vitro for the inhibition of hypoxic cellular tumor acidification in two cell lines overexpressing CA IX (colorectal carcinoma cell line HT-29 and cervical carcinoma cell line HeLa). The lead molecule 13 (Figure 4) was demonstrated to slow down tumor growth at nontoxic dose and to enhance sensitization toward radiotherapy in a CA IX dependent manner [36]. Moreover, 13 was shown to sensitize tumors toward doxorubicin-based chemotherapy in vivo, the sensitization effects being markedly higher compared with single CA IX targeting agent [33].…”
Section: Sulfonamide Sulfamate and Sulfamide For Ca Ix-directed Therapiesmentioning
Carbonic anhydrases (CAs; EC 4.2.1.1) are well known zinc metalloproteins involved in the catalysis of a very simple but essential physiological reaction: carbon dioxide hydration to bicarbonate and proton. These enzymes are of clinical relevance in cancer therapy as among the 15 isoforms known in humans, two cell surface CA isoforms, namely CA IX (almost exclusively associated with tumors) and CA XII (overexpressed in some tumor types) are involved in tumorigenesis. Targeting the tumor associated isoforms IX is now considered as a pertinent approach for the development of new cancer therapeutics against hypoxic tumors. Different approaches and new family of pharmacological agents were described in the last 5 years for obtaining compounds that specifically target CA IX over the ubiquitous cytosolic off-target isoforms CA I and CA II. The aim of this review is to give a comprehensive update on the reported discoveries in the field of CA IX inhibitors with an emphasis on the new families of compounds which reach in vivo/preclinical studies for their potential in cancer therapy.
“…The tail present in the sulphonamide CA inhibitors is essential for binding of the inhibitor within the active site. One of a novel sulfamate class of CAIX inhibitors has been shown to reduce the spread, proliferation and migration of human MBA-MB-231 breast cancer cells [68,72,73] and several recent studies have demonstrated the potential of these novel inhibitors to enhance the in vitro and in vivo effectiveness of radiotherapy using a colorectal cancer model [74,75]. Investigations in our laboratory suggest that these inhibitors may also increase the effects of radiation in several breast cancer models (unpublished data).…”
Section: Targetting the Hypoxic Microenvironmentmentioning
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.